Allogenica’s bioproduction process consists in:
Transferring therapeutic transgene to these immature cells (called pre-T cells)
2
Harvesting stem cell from healthy donors
1
Our commitment
We are committed to making T-cell therapies universally accessible by delivering treatments that are safer, more readily available to patients, and up to ten times less expensive to manufacture.
While cancer remains our primary focus, we also aim to address rare diseases and autoimmune disorders.
Inna MENKOVA, PhD
CEO and Co-founder of ALLOGENICA
WHY Allogenica
Our unique approach
4
After production, engineered pre-T cells are stored and ready to be delivered "off-the-shelf" when a patient needs them
Differentiate and expand the engineered pre-T cells at large scale in a bioreactor
3
Allogenica's unique expertise enables the differentiation of stem cells into immature precursor T cells. Allogenica's innovative vector allows these cells to be modified to produce a new generation of allogeneic T-cell therapies.
Allogenica’s most advanced drug candidate is expected to enter clinical trials in 2026.
Allogenica’s solution
Allogenica has developed unique worldwide expertise:
Latest news
COLLABORATIONS
They support Allogenica
Allogenica’s pre-T advantages:
Our Management Team
Inna Menkova, PhD
Chief Executive Officer
and co-founder
Tobias Abel, PhD
Chief Scientific Officer
Aymeric Bordet
Chief Financial Officer
VISION
Future-ready Cell Therapy
At Allogenica we are transforming cell therapies for a healthier tomorrow.
Our mission is to disrupt the treatment landscape for cancer, rare diseases, and autoimmune disorders. We're developing a breakthrough cell therapy platform with the potential to:
-
Replace transplants: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options.
-
Expand access for all: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population.
-
Dramatically reduce costs: By streamlining production, we aim to significantly lower the cost of cell therapies, making transformative treatments more accessible globally.
Here is an example of an application of the Allogenica platform that could revolutionize, for example, CAR-T therapy. Watch the video below to learn more.
A revolution in the field of cell therapy
Engineered T-cell therapies are one of the key therapies revolutionizing the healthcare landscape. The approach involves reprogramming immune cells to recognize and kill cancer cells.
But traditional T-cell therapies, even when truly effective, are long and complex to manufacture, leading to delays that are often too long for patients battling life-threatening diseases.
Board of directors
Jean-Guillaume Lafay
Chairman of the BOD and co-founder
Jean-Marie Grumel, MD
Board member and co-founder
Stephane Legastelois, PhD
President at 33 Californie
Eglantine Rollet, PhD
Investment Manager Pulsalys
Jean Pascal Tranie
Partner, Aloe Private Equity
Scientific Advisory Board
Prof. Charles Dumontet,
MD, PhD
Chairman of the SAB
Prof. Olivier Adotevi,
MD, PhD
Prof. Jean Daniel Lelièvre, MD, PhD
Julien Marie,
PhD
Join our team
-
High quality of start material
-
Biobanking
-
Great expansion capacity
-
No exhaustion markers
-
Potency assay available
Advantages for bioproduction
-
No Graft vs Host disease (no TCR expression)
-
Long-term persistence (over 10 years)
-
Efficient thymic maturation
-
Potent anti-cancer activity